Epigral's numbers hold steady, but its call undermines credibility
Revenue and margins met guidance, but management reversed its epoxy stance within six months without explanation.
The numbers
- Q1 revenue rose 16% to ₹705.36 crore, matching expectations.
- EBITDA margin of ~26% landed within the 25% guidance band.
- PAT fell to ₹99.18 crore because last year's ₹80.67 crore deferred tax credit did not recur; underlying profit grew 25%.
- CPVC utilization stood at 50-55%, weaker than anticipated.
- A wholly-owned subsidiary was incorporated for chemical manufacturing.
Management's story
- Management targets a 15-20% CAGR over 3-5 years, with an internal goal of 20% or higher growth.
- New projects could add ₹1,300-1,500 crore revenue, pushing total top line to ₹5,000 crore.
- Capex of ₹400 crore each in FY27 and FY28 will be 60% debt-funded; epoxy investment is ₹600 crore.
- Pilot facilities for epoxy and MPP are expected by Q2 FY27; MPP completion in FY28.
- Management framed the quarter as steady, despite strategic reversals.
“As of now, we have no plan to going into the forward integration... we are not taking anything on the epoxy side.”
— Epigral management, Jan 2026 call
Where they diverge
The numbers show a routine quarter: revenue growth, margin discipline, and a one-off profit dip. But the call told a different story. In January, management said it had no plan to enter epoxy; in July it approved a 125,000-ton plant with no explanation. It also reversed its view on India's caustic soda trade balance. The operational stability the filing reports is at odds with the strategic whiplash the call reveals.
The full read
Epigral delivered a clean operational quarter. Revenue rose 16% to ₹705 crore, EBITDA margin held at 26%, and profit excluding a one-off tax credit grew 25%. The numbers confirm steady execution. But the earnings call told a different story. In January, management told investors it had no plan to enter epoxy. In July, it announced board approval for a 125,000-ton epoxy resin plant with no explanation. It also reversed its view on India's caustic soda trade balance from net exporter to net importer without reconciling the change. CPVC utilization at 50-55% signals demand weaker than hoped. The growth narrative now hinges on a dramatic target revision to 20% CAGR and ₹5,000 crore revenue. But without project-level margin breakdowns or a credible strategy, investors are left connecting dots. Credibility, like a strategy, cannot be reversed every six months without cost.
What we're watching
- Epoxy pilot facility operational status by Q2 FY27.
- CPVC utilization trend in upcoming quarters; management's demand outlook.
- Net debt/EBITDA trajectory as capex ramps up; currently 0.8x from 0.6x.
- Revenue contribution from new projects by FY28.